Stroke is the leading cause of adult disability in America, and one of the leading causes of death in the world. If patients arrive at a hospital within 3 hours of their stroke beginning, thrombolytic therapy can be very effective. Only 40 to 50% of patients respond to lytic treatment, however, creating a priority to develop new, effective treatments for stroke. The brain consists of multiple cell types: neurons, glia, and endothelial cells, among others; during stroke, the brain loses 1.2 million neurons per minute. In the past, candidate stroke treatments that failed to benefit patients were targeted only at neurons. We now propose to test a new drug that powerfully protects neurons, glia, and endothelial cells, together known as the neurovascular unit. This drug, 3K3A-APC, acts on cells partly via the PAR-1 receptor to induce protection by several mechanisms. Multiple laboratories- using neurobehavioral and histomorphometric endpoints in several animal models-have shown the drug powerfully reduces the effects of experimental stroke, even when administered up to 4 hours after the stroke begins. In human volunteers, only mild and moderate side effects were detected at clinically relevant doses. We now propose to test 3K3A-APC-for the first time-in stroke patients who arrive at the hospital very early and receive thrombolytic treatment. Very low doses will be tried at first, and then progressively higher doses will be tried. Ultimately, we wil determine the maximum tolerated dose (MTD), that is, the largest drug dose that can be given without causing severe side effects. By the end of this study, we hope to determine a dose that is safe and well tolerated by patients suffering acute stroke. Should this study succeed, the next step would be a much larger study to test for possible benefit of 3K3A-APC in stroke patients.
The brain consists of multiple cell types: neurons (nerve cells), glia (connection cells), and endothelial cells (the blood vessels). During stroke, the brai loses 1.2 million neurons per minute, so time is brain. In the past, candidate stroke treatments that failed to benefit patients were targeted only at neurons. We now propose to test a new drug, known as 3K3A-APC that powerfully protects neurons, glia, and endothelial cells by causing the cells to activate a variety of protective proteins and block the cell death process.
| Lyden, Patrick D (2018) When less is more (brain)-comment on ""Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage"". Ann Neurol 83:446-448 |
| Dumitrascu, Oana M; Torbati, Sam; Tighiouart, Mourad et al. (2017) Pitfalls and Rewards for Implementing Ocular Motor Testing in Acute Vestibular Syndrome: A Pilot Project. Neurologist 22:44-47 |
| Lyden, Patrick; Weymer, Sara; Coffey, Chris et al. (2016) Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke 47:2979-2985 |
| Griffin, John H; Fernández, José A; Lyden, Patrick D et al. (2016) Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. Thromb Res 141 Suppl 2:S62-4 |
| Lyden, Patrick (2015) Why don't more patients receive intravenous rt-PA for acute stroke? Expert Rev Neurother 15:571-4 |
